Speciality Medicines Ltd.
SPECIALITYSME
Ask IPO
Overview
Speciality Medicines Limited is a pharmaceutical company engaged in marketing and distributing finished formulations of specialty products, including high-cost oral and injectable medications for complex and chronic conditions in areas like oncology, immunology, and neurology. The company operates through two integrated business models: international distribution of products manufactured on a contract basis, and marketing and distribution of specialty pharmaceutical products sourced from other manufacturers. Speciality Medicines Limited offers a diverse portfolio of products in various dosage forms such as tablets, capsules, injections, and syrups, serving markets in India and over 35 countries globally.
Opening Date
Mar 20, 2026
Closing Date
Mar 24, 2026
Listing Date
Mar 30, 2026
IPO Type
SME
IPO Status
Closed
Issue Size
29.14 Cr
Fresh Issue
29.14 Cr
Offer for Sale
0 Cr
Price Band
₹117 - ₹124
Lot Size
1000
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
Our Company intends to utilize the Net Proceeds for the following objects:
- •
Setting up a comprehensive Research and Development (R&D) Center in Valsad, Gujarat, to internalize formulation development, reduce reliance on third parties, and accelerate product innovation.
- •
Funding product registration and development activities for international markets, including preparing and submitting dossiers to regulatory authorities in countries like Ethiopia, Namibia, and Jordan to expand global footprint.
- •
Allocating funds for strategic marketing and brand promotion activities, including participation in major international pharmaceutical exhibitions to enhance brand visibility and generate new business leads.
- •
Meeting the company's growing working capital requirements to support the expanding scale of domestic and international business operations.
- •
Financing general corporate purposes, which may include strategic initiatives, unforeseen contingencies, and other operational expenses not covered by other objectives.
Key Performance Indicator
P/E Ratio
9.27
EPS
13.38
ROE
18.11%
ROCE
16.68%
RONW
16.61%
Debt to Equity Ratio
—
PAT Margin
16.49%
EBITDA Margin
17.73%
P/B
2.19
SWOT Analysis
Strengths
- •
GDP-certified distributor with compliance to Good Distribution Practices, strengthening credibility with global partners.
- •
Strong global export network supplying specialty drugs and generics to over 35 countries.
- •
Sourcing from WHO-GMP & ISO 9001-certified manufacturers, ensuring product traceability and quality.
- •
Offers a wide and diversified range of both registered and unregistered pharmaceutical products.
Weaknesses
- •
Limited in-house manufacturing presence, leading to potential margin pressure and dependency on third-party sourcing.
- •
Nascent brand visibility in the market compared to larger, established listed pharmaceutical companies.
- •
Operational concentration with limited geographic warehousing capabilities, which may constrain broader reach.
Opportunities
- •
Rising global demand for specialty drugs, particularly in oncology, biologics, and rare-disease medications.
- •
Expansion into new and emerging geographies such as Africa, Latin America, and the Middle East.
- •
Potential for institutional tie-ups and bulk supply contracts for NGO programs and clinical trials.
- •
Introducing value-added services like pharmacovigilance support and specialized refrigerated distribution.
Threats
- •
Intensifying competition from large, well-capitalized distributors with greater scale and infrastructure.
- •
Vulnerability to global supply-chain disruptions, including API shortages and logistics delays.
- •
Potential for margin compression due to stringent government pricing controls on specialty drug categories.
- •
Risk of technology obsolescence and operational inefficiencies without timely investment in modern systems.
Subscription Rate
Frequently Asked Questions about Speciality Medicines Ltd.
Speciality Medicines Limited is a pharmaceutical company engaged in marketing and distributing finished formulations of specialty products, including high-cost oral and injectable medications for complex and chronic conditions in areas like oncology, immunology, and neurology. The company operates through two integrated business models: international distribution of products manufactured on a contract basis, and marketing and distribution of specialty pharmaceutical products sourced from other manufacturers. Speciality Medicines Limited offers a diverse portfolio of products in various dosage forms such as tablets, capsules, injections, and syrups, serving markets in India and over 35 countries globally.
The Speciality Medicines Ltd. IPO is scheduled to open for subscription on Mar 20, 2026 and close on Mar 24, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Speciality Medicines Ltd. IPO is ₹117 to ₹124. Investors can place bids within this range once the issue opens.
The minimum lot size for the Speciality Medicines Ltd. IPO is 1000 shares. The minimum investment amount ₹1,24,000.
The total issue size of the Speciality Medicines Ltd. IPO is approximately ₹29.14. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Speciality Medicines Ltd. IPO has been subscribed 0.94 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Speciality Medicines Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Speciality Medicines Ltd. are expected to list on stock exchanges on Mar 30, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Speciality Medicines Ltd. IPO are proposed to be used for Our Company intends to utilize the Net Proceeds for the following objects:, Setting up a comprehensive Research and Development (R&D) Center in Valsad, Gujarat, to internalize formulation development, reduce reliance on third parties, and accelerate product innovation., Funding product registration and development activities for international markets, including preparing and submitting dossiers to regulatory authorities in countries like Ethiopia, Namibia, and Jordan to expand global footprint., Allocating funds for strategic marketing and brand promotion activities, including participation in major international pharmaceutical exhibitions to enhance brand visibility and generate new business leads., Meeting the company's growing working capital requirements to support the expanding scale of domestic and international business operations., Financing general corporate purposes, which may include strategic initiatives, unforeseen contingencies, and other operational expenses not covered by other objectives.
Before applying for the Speciality Medicines Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
